

## **Pharmacy Drug Policy Checklist**

POLICY NAME Oriahnn (elagolix, estradiol, and norethindrone) POLICY # 2841P

## Criteria

Coverage Criteria for Uterine Leiomyomas (Fibroids)	
	1.1 Diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
	1.2 Age 18 years or older
	1.3 Patient is premenopausal
	1.4 Documented history of inadequate control of bleeding following a trial of at least 3 months, intolerance, or contraindication to one of the following: estrogen combination (estrogen/ progesterone) oral contraceptive, progestins, or tranexamic acid, OR
	<b>1.5</b> Documentation of a previous interventional therapy to reduce bleeding (e.g., uterine-artery embolization, magnetic resonance-guided focused ultrasonography)
Exclusion Criteria – Any of the following prevents coverage	
	2.1 Treatment duration beyond 24 months
	2.2 Oriahnn will not be approved if being used in combination with Lupron